Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) – Stock analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for Harmony Biosciences in a research note issued on Monday, July 1st. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will earn $2.62 per share for the year, up from their previous estimate of $2.45. Cantor Fitzgerald currently has a “Overweight” rating and a $49.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.02 per share.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last released its earnings results on Tuesday, April 30th. The company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.07. Harmony Biosciences had a return on equity of 28.26% and a net margin of 22.30%. The firm had revenue of $154.62 million during the quarter, compared to analysts’ expectations of $154.10 million. During the same period in the prior year, the company earned $0.48 earnings per share. The company’s quarterly revenue was up 29.8% on a year-over-year basis.
View Our Latest Report on HRMY
Harmony Biosciences Price Performance
Shares of NASDAQ:HRMY opened at $30.89 on Wednesday. Harmony Biosciences has a one year low of $18.61 and a one year high of $39.26. The company has a market cap of $1.75 billion, a price-to-earnings ratio of 13.37, a PEG ratio of 0.66 and a beta of 0.72. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.11 and a quick ratio of 3.07. The firm has a 50 day simple moving average of $30.04 and a 200 day simple moving average of $31.18.
Institutional Trading of Harmony Biosciences
Several institutional investors and hedge funds have recently modified their holdings of the stock. Exchange Traded Concepts LLC boosted its holdings in shares of Harmony Biosciences by 0.8% in the 4th quarter. Exchange Traded Concepts LLC now owns 40,889 shares of the company’s stock worth $1,321,000 after buying an additional 328 shares during the last quarter. Quadrant Capital Group LLC increased its holdings in Harmony Biosciences by 47.5% during the 4th quarter. Quadrant Capital Group LLC now owns 1,022 shares of the company’s stock worth $33,000 after acquiring an additional 329 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Harmony Biosciences by 1.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 35,272 shares of the company’s stock worth $1,184,000 after buying an additional 397 shares in the last quarter. Texas Permanent School Fund Corp raised its holdings in shares of Harmony Biosciences by 1.8% in the 1st quarter. Texas Permanent School Fund Corp now owns 28,706 shares of the company’s stock valued at $964,000 after acquiring an additional 517 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in Harmony Biosciences by 7.0% in the 1st quarter. ProShare Advisors LLC now owns 10,488 shares of the company’s stock worth $352,000 after buying an additional 684 shares in the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Featured Stories
- Five stocks we like better than Harmony Biosciences
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- What is the Nikkei 225 index?
- AbbVie Stock: A Perfect Dip for Investors to Buy
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.